title: Oxybutynin-induced reflux esophagitis.
abstract: Oxybutynin has less anticholinergic activity than propantheline bromide. Therefore, oxybutynin is often preferentially prescribed for patients at risk of morbid complications of atropine-like adverse effects. We report a case of oxybutynin-induced reflux esophagitis. This probably resulted from the anticholinergic action of oxybutynin, which decreased lower esophageal sphincter tone. We outline a management approach for patients who experience this adverse effect due to oxybutynin or other commonly prescribed medications.
authors.affiliation: College of Pharmacy, University of Illinois, Chicago 60612.
authors.forename: M
authors.initials: M
authors.lastname: Lee
authors.forename: R
authors.initials: R
authors.lastname: Sharifi
mesh_terms: D000328:Adult; D002547:Cerebral Palsy / Q000150:complications; D004942:Esophagitis, Peptic / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000009:adverse effects*; D010276:Parasympatholytics / Q000009:adverse effects*
chemical_list: D008333:Mandelic Acids; D010276:Parasympatholytics; C005419:oxybutynin